VEGFA and neoplasm: In Phase II clinical trials (MHRA 21313/0007), Siltuximab showed significant reductions in IL6, CCL2, CXCL12, and VEGF levels, leading to decreased angiogenesis and macrophage infiltration, further validating the potential of Siltuximab in altering the tumor microenvironment.